99 related articles for article (PubMed ID: 14575575)
1. [Relationship of PTEN, Mdm2 and p53 expression in astrocytoma].
Zhong XY; Sun YH; Chen YX
Zhonghua Zhong Liu Za Zhi; 2003 Sep; 25(5):478-81. PubMed ID: 14575575
[TBL] [Abstract][Full Text] [Related]
2. Characterisation of molecular alterations in microdissected archival gliomas.
Walker C; Joyce KA; Thompson-Hehir J; Davies MP; Gibbs FE; Halliwell N; Lloyd BH; Machell Y; Roebuck MM; Salisbury J; Sibson DR; Du Plessis D; Broome J; Rossi ML
Acta Neuropathol; 2001 Apr; 101(4):321-33. PubMed ID: 11355303
[TBL] [Abstract][Full Text] [Related]
3. Could changes in the regulation of the PI3K/PKB/Akt signaling pathway and cell cycle be involved in astrocytic tumor pathogenesis and progression?
Hlobilkova A; Ehrmann J; Sedlakova E; Krejci V; Knizetova P; Fiuraskova M; Kala M; Kalita O; Kolar Z
Neoplasma; 2007; 54(4):334-41. PubMed ID: 17822324
[TBL] [Abstract][Full Text] [Related]
4. PTEN reverses MDM2-mediated chemotherapy resistance by interacting with p53 in acute lymphoblastic leukemia cells.
Zhou M; Gu L; Findley HW; Jiang R; Woods WG
Cancer Res; 2003 Oct; 63(19):6357-62. PubMed ID: 14559824
[TBL] [Abstract][Full Text] [Related]
5. [Expression of P21 WAF1/CIP1 in human astrocytomas in correlating with P53, MDM2, and cellular proliferation index].
Xu QZ; Liu F; Lu DH; Yu SZ; Yang H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Aug; 23(4):341-5. PubMed ID: 12940073
[TBL] [Abstract][Full Text] [Related]
6. Genetic profile of gliosarcomas.
Reis RM; Könü-Lebleblicioglu D; Lopes JM; Kleihues P; Ohgaki H
Am J Pathol; 2000 Feb; 156(2):425-32. PubMed ID: 10666371
[TBL] [Abstract][Full Text] [Related]
7. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
8. PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy.
Mayo LD; Dixon JE; Durden DL; Tonks NK; Donner DB
J Biol Chem; 2002 Feb; 277(7):5484-9. PubMed ID: 11729185
[TBL] [Abstract][Full Text] [Related]
9. [Expression of PTEN, p16, p21, and p53 proteins in lung cancer using tissue microarray and their clinical significance].
Liao XB; Hu DX; Zhou XM; Yu FL; Yuan YC; Chen MJ
Ai Zheng; 2004 Mar; 23(3):334-8. PubMed ID: 15025970
[TBL] [Abstract][Full Text] [Related]
10. PTEN and p53 abnormalities are indicative and predictive factors for endometrial carcinoma.
Inaba F; Kawamata H; Teramoto T; Fukasawa I; Inaba N; Fujimori T
Oncol Rep; 2005 Jan; 13(1):17-24. PubMed ID: 15583796
[TBL] [Abstract][Full Text] [Related]
11. The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network.
Mayo LD; Donner DB
Trends Biochem Sci; 2002 Sep; 27(9):462-7. PubMed ID: 12217521
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified.
Mayo LD; Seo YR; Jackson MW; Smith ML; Rivera Guzman J; Korgaonkar CK; Donner DB
J Biol Chem; 2005 Jul; 280(28):25953-9. PubMed ID: 15843377
[TBL] [Abstract][Full Text] [Related]
13. Correlation of molecular genetic analysis of p53, MDM2, p16, PTEN, and EGFR and survival of patients with anaplastic astrocytoma and glioblastoma.
Ushio Y; Tada K; Shiraishi S; Kamiryo T; Shinojima N; Kochi M; Saya H
Front Biosci; 2003 May; 8():e281-8. PubMed ID: 12700122
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of Mdm2, p53 and p16 in patients with astrocytomas.
Ranuncolo SM; Varela M; Morandi A; Lastiri J; Christiansen S; Bal de Kier Joffé E; Pallotta MG; Puricelli L
J Neurooncol; 2004 Jun; 68(2):113-21. PubMed ID: 15218947
[TBL] [Abstract][Full Text] [Related]
16. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
17. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
18. Molecular genetic analysis of non-astrocytic gliomas.
Tong CY; Ng HK; Pang JC; Hui AB; Ko HC; Lee JC
Histopathology; 1999 Apr; 34(4):331-41. PubMed ID: 10231401
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(3A):1689-95. PubMed ID: 9673391
[TBL] [Abstract][Full Text] [Related]
20. Prognostic factors in astrocytomas: relationship of p53, MDM-2, BCL-2 and PCNA immunohistochemical expression to tumor grade and overall patient survival.
Ehrmann J; Kolár Z; Vojtĕsek B; Kala M; Komenda S; Oulton A
Neoplasma; 1997; 44(5):299-304. PubMed ID: 9473789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
